Effects of Short-Term Propylthiouracil Treatment on P Wave Duration and P Wave Dispersion in Patients with Overt Hypertyroidism

Abstract

Background: P-wave duration is defined as the time measured from the onset to the offset of the P-wave in surface electrocardiogram (ECG). Prolonged P wave duration and increased P wave dispersion (PWD) have been reported to carry an increased risk for atrial fibrillation.

Aim: Our aim was to evaluate the role of hyperthyroidism on P wave duration and dispersion, to investigate the effect of anti-thyroid therapy on P wave duration and dispersion.

Material and methods: A total of 44 consecutive subjects (22 patients with newly diagnosed overt hyperthyroidism and 22 randomly selected euthyroid healthy subjects) were enrolled in the study. Transthoracic echocardiography, 12 lead surface ECG and thyroid hormone levels were studied at the time of enrollment, in the first and third months of the 6-8 mg/kg/day propylthiouracil therapy. Patients were followed-up for 3 months.

Results: Patient and control groups were consisted of age and sex matched subjects. Baseline left atrial diameter was similar between the patient and control groups (3.4±0.3 cm and 3.4±0.3 cm respectively, p=0.813). The maximum P-wave duration (P maximum) was 113.1±6.6 and 105.7±4.1 ms in patient and control groups (p=0.001). PWD was 31.5±9.5 and 25.2±5.9 ms in patient and control groups respectively (p=0.015). At the third month of propylthiouracil treatment P maximum and PWD were decreased in the patient group at statistically significant level and returned back in normal limits (p<0.001 and p=0.001).

Conclusion: P wave duration and PWD are found prolonged in hyperthyroid patients and propylthiouracil treatment decreased them effectively. This mechanism may establish how the anti-thyroid treatment may prevent the development of atrial fibrillation in hyperthyroid patients.

Hyperthyroidism - propylthiouracil treatment - p wave duration - p wave dispersion

References

• 1 Klein I, Ojamaa K. Thyrotoxicosis and the heart.  Endocrinol Metab Clin North Am. 1998;  27 51-62
• 2 Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of “idiopathic” atrial fibrillation.  Am J Cardiol. 1979;  44 9-12
• 3 Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation.  Am J Med. 1996;  101 413-421
• 4 Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Eng J Med. 1994;  331 1249-1252
• 5 Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE, Toutouzas PK. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation.  Am Heart J. 1998;  135 733-738
• 6 Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, Acil T, Nazli N, Ozmen F, Oto A, Kes S. P-wave dispersion on 12-lead electrocardiogram in patients with paroxysmal atrial fibrillation.  Pacing Clinical Electrophysiology. 2000;  23 1109-1112
• 7 Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Sciacca R, Menchavez E. Value of P wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery.  Circulation. 1993;  88 1622-2618
• 8 Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE. Clinical and electrocardiographic predictors of recurrent atrial fibrillation.  Pacing Clinical Electrophysiology. 2000;  23 352-358
• 9 Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system.  N Engl J Med. 2001;  344 501-509
• 10 Ma ML, Watanabe K, Watanabe H, Hosaka Y, Komura S, Aizawa Y, Yamamoto T. Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats.  Jpn Heart J. 2003;  44 101-110
• 11 Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state.  Am J Med. 1982;  72 903-906
• 12 Moe GK, Abildskov JA. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge.  Am Heart J. 1959;  58 59-70
• 13 Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs.  Circ Res. 1988;  62 395-410
• 14 Cetinarslan B, Akkoyun M, Canturk Z, Tarkun I, Kahranman G, Komsuoglu B. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism.  Endocr Pract. 2003;  9 200-203
• 15 Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E, Demir AD, Soylu MO, Erdogan MF, Kisacik HL, Korkmaz S. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism.  Int J Cardiol. 2005;  99 59-64
• 16 Cooper DS. Antithyroid drugs.  N Engl J Med. 2005;  352 905-917

Correspondence